Compare STOK & STRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STOK | STRA |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Consumer Services |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.8B |
| IPO Year | 2019 | 1996 |
| Metric | STOK | STRA |
|---|---|---|
| Price | $36.53 | $83.46 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 3 |
| Target Price | $39.20 | ★ $92.67 |
| AVG Volume (30 Days) | ★ 687.2K | 229.3K |
| Earning Date | 05-12-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 2.88% |
| EPS Growth | ★ 92.73 | 15.85 |
| EPS | N/A | ★ 5.41 |
| Revenue | $184,420,000.00 | ★ $997,137,000.00 |
| Revenue This Year | N/A | $3.93 |
| Revenue Next Year | $77.49 | $4.93 |
| P/E Ratio | ★ N/A | $15.38 |
| Revenue Growth | ★ 404.50 | 57.23 |
| 52 Week Low | $8.30 | $72.17 |
| 52 Week High | $40.22 | $92.98 |
| Indicator | STOK | STRA |
|---|---|---|
| Relative Strength Index (RSI) | 58.53 | 54.88 |
| Support Level | $30.34 | $79.21 |
| Resistance Level | $39.00 | $85.58 |
| Average True Range (ATR) | 1.77 | 2.10 |
| MACD | 0.34 | -0.04 |
| Stochastic Oscillator | 84.76 | 64.71 |
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
Strategic Education Inc. is an education services company that provides access to high-quality education through campus-based and online post-secondary education offerings, as well as through programs to develop job-ready skills for high-demand markets. The company operates through wholly-owned subsidiaries Strayer University and Capella University, both accredited post-secondary institutions of higher education located in the United States, as well as Torrens University, an accredited post-secondary institution of higher education located in Australia. It provide employees with access to affordable and industry relevant training, certificate, and degree programs. The reportable segments of the company are U.S. Higher Education, Australia/New Zealand and Education Technology Services.